O Hospital Universitário Bettina Ferro de Souza (HUBFS) oferece ensino, pesquisa e atendimento especializado gratuito em Oftalmologia, Otorrinolaringologia e Pediatria na Região Norte.
O Atlas Brasileiro Online de Doenças Raras é um serviço da Rede Nacional de Doenças Raras. Ele foi criado para disseminar informações sobre epidemiologia, quadro clínico, recursos diagnósticos e terapêuticos usados, e custos relacionados a doenças raras de origem genética e não genética no Brasil.
As doenças raras podem ser definidas como aquelas que afetam até 65 pessoas em cada 100 mil, ou seja, 1,3 pessoas para cada 2.000 indivíduos. No Brasil, estima-se que cerca de treze milhões de pessoas possuem alguma doença rara.
Após coletar, armazenar, processar e analisar os dados provenientes do projeto Rede Nacional de Doenças Raras, produzimos e publicamos estudos científicos para revistas e conferências científicas nacionais e internacionais.
Portanto, bem-vindo(a) a nossa lista de publicações. Essas publicações científicas representam um esforço contínuo para o entendimento e a explicação de fenômenos na área das doenças raras.
Esses esforços visam fornecer subsídios úteis e relevantes para a tomada de decisão baseadas em evidências no campo das doenças raras. Corroborando assim para o cumprimento dos objetivos gerais e específicos deste projeto.
Oliveira BM, Baiochi JF, Milke JC, Lorea CF, Viegas I, Bernardi FA, Alves D, Schwartz IVD, Félix TM, RARAS Network Group
BACKGROUND: Inborn errors of metabolism (IEM) present significant challenges in diagnosis and management. The Brazilian Rare Diseases Network (BRDN) is a consortium of 40 healthcare centers from all five regions of Brazil established in 2020, designed to perform an epidemiological survey on rare diseases (RD). This study aims to present comprehensive data on patients with IEM assisted in the centers of BRDN, including their clinical profiles, diagnosis, and treatments applied. METHODS: We conducted a comprehensive review of all cases with confirmed or suspected IEM in BRDN. Selection criteria were established using the Rare IEM classification from Orphadata (v. Dec 4, 2023, https: //www.orphadata.com/classifications/), incorporating ICD-10, OMIM, and Orpha diagnostic codes. A retrospective (2018-2019) and prospective (2022-2024) data collection was conducted using a RedCap standard form. RESULTS: Of 19,307 total records at BRDN, 2,667 (13.8%) IEM cases were registered (retrospective phase: 1,798/12,285; prospective phase: 870/7022). Most participants (32.4%) lived in the Southeast region of Brazil. The mean age at inclusion was 18.0 years (±15.5), and 1,402 (52.6%) were female. Diagnosis of IEM was confirmed in 88.3% and suspected in 11.7%. For RD coding, Orpha was mostly (71.4%) used. The most frequent diagnoses were Phenylketonuria (PKU, n=762), Mucopolysaccharidosis (MPS) type 2 (n=102), Fabry disease (n=95), MPS type 6 (n=89) and Gaucher disease (n=86). Biochemical diagnosis was performed in 66.6% of cases, molecular diagnosis was conducted in 25.7%, and the remaining cases were categorized as Others. Only 26.2% were diagnosed through newborn screening. The most recorded Human Phenotype Ontology were: Reduced phenylalanine hydroxylase level, Seizure, and Hyperphenylalaninemia. Positive family history was registered in 27.1% and 16.5% reported consanguinity. In the retrospective phase, specific treatment for IEM was reported in 71.6% of cases. Within the overall cohort, 41.2% received diet therapy. Previous hospitalizations were documented in 88.3%. The mortality rate was 1.8% during the retrospective phase. CONCLUSIONS: This study shows the first Brazilian nationwide data on IEM, demonstrating the importance of networking between specialized RD centers. PKU is included in the Brazilian Newborn Screening Program, leading to higher diagnostic prevalence. This data may contribute to improving the assistance of IEM in Brazil.
Bibiana Mello de Oliveira, Raras Network Group
Abstract Background The Brazilian Policy for Comprehensive Care for People with Rare Diseases was implemented in 2014; however, national epidemiological data on rare diseases (RDs) are scarce and mainly focused on specific disorders. To address this gap, University Hospitals, Reference Services for Neonatal Screening, and Reference Services for Rare Diseases, all of which are public health institutions, established the Brazilian Rare Diseases Network (RARAS) in 2020. The objective of this study was to perform a comprehensive nationwide epidemiological investigation of individuals with RDs in Brazil. This retrospective survey collected data from patients receiving care in 34 healthcare facilities affiliated with RARAS in 2018 and 2019. Results The survey included 12,530 participants with a median age of 15.0 years, with women representing 50.5% of the cohort. Classification according to skin color demonstrated that 5044 (47.4%) participants were admixed. Most had a confirmed diagnosis (63.2%), with a predominance of phenylketonuria (PKU), cystic fibrosis (CF), and acromegaly. Common clinical manifestations included global developmental delay and seizures. The average duration of the diagnostic odyssey was 5.4 years (± 7.9 years). Among the confirmed diagnoses, 52.2% were etiological (biochemical: 42.5%; molecular: 30.9%), while 47.8% were clinical. Prenatal diagnoses accounted for 1.2%. Familial recurrence and consanguinity rates were 21.6% and 6.4%, respectively. Mainstay treatments included drug therapy (55.0%) and rehabilitation (15.6%). The Public Health System funded most diagnoses (84.2%) and treatments (86.7%). Hospitalizations were reported in 44.5% of cases, and the mortality rate was 1.5%, primarily due to motor neuron disease and CF. Conclusion This study marks a pioneering national-level data collection effort for rare diseases in Brazil, offering novel insights to advance the understanding, management, and resource allocation for RDs. It unveils an average diagnostic odyssey of 5.4 years and a higher prevalence of PKU and CF, possibly associated with the specialized services network, which included newborn screening services.
Juliana F. Mazzeu , Halinna Dornelles-Wawruk, Romina Soledad Heredia, Milton R. de Paula-Junior , Maria Terezinha O. Cardoso, Raphael S. Bonadio, Bianca F. dos Reis, Aline Pic-Taylor, Silviene F. de Oliveira
Long intergenic noncoding RNAs (lincRNAs) are a class of noncoding RNAs implicated in several biological processes. LincRNA 299 ( LINC00299 ) maps to 2p25.1 and its function is still unknown. However, this gene has been proposed as a candidate for intellectual disability (ID) in a patient with a balanced translocation where the breakpoint disrupted its ORF. Here, we describe a new case of LINC00299 disruption associated with ID. The individual, a 42-year-old woman, was referred to the clinical geneticist because of her son who had severe syndromic ID. G-banding and chromosomal microarray analysis were performed. Karyotyping of the boy revealed an extranumerary derivative chromosome identified as an unbalanced translocation between chromosomes 2 and 9 of maternal origin. The mother's karyotype showed a balanced translocation 46,XX,t(2;9)(p25;q13). Chromosomal microarray indicated a disruption of LINC00299 . These data corroborate the role of LINC00299 as a causative gene for ID and broadens the spectrum of LINC00299 -related phenotypes
Para quaisquer dúvidas, comentários, problemas técnicos e sugestões relacionadas ao Atlas Brasileiro Online de Doenças Raras, entre em contato conosco através do formulário abaixo ou do nosso e-mail de suporte a qualquer momento: suporte@raras.org.br
Para maior comodidade, também é possível preencher nosso formulário de contato online. Preencha o formulário a seguir com suas informações e sua mensagem. Nossa equipe responderá assim que possível.
Valorizamos todos os comentários, sugestões e feedbacks. Eles nos auxiliam no processo de melhoria contínua de nosso Atlas Brasileiro Online de Doenças Raras. Compartilhe sua experiência conosco a qualquer momento.
Ministério da Saúde do Brasil
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Departamento de Ciência e Tecnologia
Em breve entraremos em contato.
Lamentamos o ocorrido, por favor tente novamente.